logo

Global Marketing : Assignment

   

Added on  2021-06-29

6 Pages1772 Words56 Views
Name: Nguyen Ngoc Ky ThoaClass: IB1401Global MarketingMEDIPAL HOLDINGS CORPORATION JAPAN1.INTRODUCTIONMEDIPAL Group is one of the largest connecting groups linking manufacturers, health organizations and retailers.MEDIPAL has built a wholesaler system that efficiently and reliably delivers the required products at the required time, in just the required amount, by connecting manufacturers in the pharmaceuticals, health, and beauty fields with medical institutions, dispensing pharmacies and retailersall over the country, through its independently developed state-of-the-art distribution centers.The basis of the wholesale business is the sourcing of products from manufacturers and the subsequent delivery to customers. However, the pharmaceutical wholesaling in Japan differs from those in Europe and the United States in the way that there are many manufacturers and customers. The existence of MEDIPAL wholesalers:Simplifies distribution channelsMakes it possible to handle everything from purchase to delivery in-houseCreates close relationships with all clients: pharmaceutical companies, medical institutions, and dispensing pharmacies.

2.MEDIPAL HOLDINGS RANK ON FORTUNE GLOBAL 5002010201120122013201420152016201720182019295309310330411454424381418436Medipal rankings on the global 500 for the past 3 years have not changed much. However, from 2010 onwards, Medipal has dropped from 295 to 436 due to the strong growth of other industries such as tourism, entertainment, technologies, aircraft, etc. Apart from that, profit of MEDIPAL still increases steadily over years. Since 2013, the Government of Japan has decided to allow more than 99% of over-the-counter medicines to be sold through the Internet in Japan. This action aims to create convenience for consumers and encourage price competition which in turn can help create a solid foundation for the Japanese pharmaceutical industry, while also contributing to expanding the online business.3.MACRO ENVIRONMENTa.Economics and financial conditionsIncome statementsMillions $March 2018March 2019March 2020Revenue28,388.2728,693.3029,920.43Gross Profit1,938.441,989.462,062.49Operating Income399.35446.08488.48Profit before tax572.63572.26694.73Net Income313.80309.83349.21Diluted EPS1.351.301.52March 2018During the fiscal year under review, Medipal Pharmaceuticals wholesale business was stable due to a recovery in personal spending against the backdrop of increased consumer confidence, as well as an increase in demand from visitors to Japan. In this environment, MEDIPAL worked to enhance safe, secure, high-quality and low-cost distribution functions.In ended March 31, 2018, the Japanese economy continued on a adequate rising trend since a result of the positive impact of government economic policies and improvement in the employment and income environment.March 2019During March 2019, the economy of Japan continued on a moderate rising trend as a result of the positive impact of government economic policies and improvement in the employment and income environment.

Sales of prescription pharmaceuticals were flat compared with the March 2018 fiscal year as factors consisting of growth in sales of new drugs offset the impact of National Health Insurance (NHI) drug price revisions implemented on April 1, 2018 and promotion of the use of generic drugs.Gross profit on ended March 31, 2019 was $1,989.46 million, contributing to improved business results overall. Operating profit reached a record high of $446.08 million, an increase of 12.6% year on year. The operating profit ratio also rose 0.2 percentage points from the previous fiscal year to 1.6%. This increase was due primarily to a 0.06 percentage point rise in the ratio of gross profit to sales and a 0.1 percentage point decline in the ratio of selling, general and administrative expenses to sales.March 2020Consolidated net sales for the period totaled $349.21 million (2.2% increase compared with March 2019), operating profit was $488.48 million (6.6% increase). While the fiscal year ended March 31 2020 initially saw a gradual recovery in Japan’s economy, reflecting the effects of government economic policies and improvements in employment and income and other factors, harsh conditions caused by the global COVID-19 pandemic are now ongoing, includinga downturn in economic activity. The MEDIPAL Group is devoting its full efforts to supporting people’s lives and lifestyles with the mission of providing steady supplies of products at any time.b.Political and government forcesThe spread of counterfeit drugs is becoming a severe problem worldwide. However, there is no door for counterfeit drugs to enter the Japanese drug market. The main reasons for this are the development of laws (the Pharmaceutical and Medical Device Act, etc) and compliance with these laws, as well as the fact that nearly all prescription pharmaceutical distribution (roughly 96%) is performed by pharmaceutical wholesalers.In that sense, the Japanese pharmaceutical wholesale industry is also responsible for safety and social costs. The MEDIPAL Group conducts lot traceability management, and employs a system that allows it todetermine what has been sold, when, to whom, and in what quantities.In the event of a voluntary product recall by a pharmaceutical company, this system allows the MEDIPALGroup, at the pharmaceutical company’s request, to rapidly provide information to the medical institutions and other customers to whom the products have been sold, and recall those products.c.Social and environment forcesWith regard to the distribution functions that are one of MEDIPAL's strengths, they are striving to further raise productivity and develop functions in order to respond to long-term environmental changes such as the decrease in the working-age population due to the declining birthrate and aging population, and the increase in specialty pharmaceuticals.Disaster planning:

End of preview

Want to access all the pages? Upload your documents or become a member.

Related Documents
Marketing Management (Solved)
|14
|4203
|468

Business Organizations & Environments in a Global Context
|13
|3357
|247

Country Risk in Pharmaceutical Industry: China vs South Africa
|18
|3757
|63

The Macroeconomic Environment of Australia and the Role of Fiscal Policy
|22
|3984
|2

AstraZeneca And Its Environment
|1
|659
|29

Marketing Plan - Assignment Sample
|60
|3627
|73